Market Overview

UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review

Share:
Related PFE
Could M&A Boost Pfizer More? Jefferies Thinks So
Benzinga's M&A Chatter for Thursday May 21, 2015
Amgen's Cholesterol Fighting Drug Receives EU Approval (GuruFocus)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), but lowered the price target from $33.00 to $32.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Pfizer closed on Thursday at $27.48.

Latest Ratings for PFE

DateFirmActionFromTo
Apr 2015Deutsche BankMaintainsBuy
Apr 2015JP MorganMaintainsOverweight
Mar 2015JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...